Literature DB >> 34282256

Clinicopathologic profiling and oncologic outcomes of secretory carcinoma of the breast.

Piguo Gong1, Chen Xia2, Yifeng Yang1, Wang Lei3, Weiping Yang1, Junhua Yu1, Yishun Ji1, Lijun Ren1, Fugui Ye4.   

Abstract

Secretory carcinoma of the breast (SCB) is a rather rare entity of invasive breast cancer, the clinicopathologic characteristics and survival outcomes remain to be elaborated. A retrospective review was conducted in SEER database. A total of 190 SCB patients identified in SEER were eligible for inclusion in the analysis. Median age at diagnosis was 56 years (range 2-96 years). Both sexes and bilateral breast could be affected. Intriguingly, the incidence of SCB tended towards to decreasing in recent decades. Small tumor burden was observed with a mean tumor size of 2.13 cm. In a subgroup with sufficient details, positive staining of estrogen receptor (ER) and progesterone receptor (PR) was 58% and 40%, respectively. The vast majority of patients were of well to moderate differentiation (86.86%) and negative regional lymph nodes involvement (70.71%). Nearly half of the patients took radiotherapy and chemotherapy. Seniors were inclined to have an inferior breast cancer specific survival (BCSS) than their younger counterparts (P = 0.018). Patients underwent breast conserving surgery (BCS) and radiotherapy had much better BCSS than its mastectomy counterparts (P = 0.014). Collectively, SCB is a clinical indolent invasive breast cancer with excellent prognosis. BCS in conjunction with radiotherapy would be a rational alternative for this distinct entity.
© 2021. The Author(s).

Entities:  

Year:  2021        PMID: 34282256     DOI: 10.1038/s41598-021-94351-w

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  1 in total

1.  Secretory carcinoma of the breast and its histopathological mimics: value of markers for differential diagnosis.

Authors:  Tomo Osako; Kengo Takeuchi; Rie Horii; Takuji Iwase; Futoshi Akiyama
Journal:  Histopathology       Date:  2013-08-14       Impact factor: 5.087

  1 in total
  1 in total

1.  PTHrP induces STAT5 activation, secretory differentiation and accelerates mammary tumor development.

Authors:  Diego Y Grinman; Kata Boras-Granic; Farzin M Takyar; Pamela Dann; Julie R Hens; Christina Marmol; Jongwon Lee; Jungmin Choi; Lewis A Chodosh; Martin E Garcia Sola; John J Wysolmerski
Journal:  Breast Cancer Res       Date:  2022-04-19       Impact factor: 8.408

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.